Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2936
Abstract: Using pharmacogenetics (PGx) to inform clinical decision making can benefit patients but clinical use of PGx testing has been limited. Existing genetics data obtained in the course of research could be used to identify patients… read more here.
Keywords: dpyd; dpyd testing; data repository; suspected dpyd ... See more keywords
The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-019-0423-8
Abstract: BackgroundDeleterious polymorphisms in the gene encoding DPD (DPYD) may result in severe reduction of DPD enzymatic activity that causes life-threatening toxicities when the standard dose of fluorouracil is used. The best panel of single-nucleotide polymorphism… read more here.
Keywords: dpyd; candidate fluoropyrimidine; fluoropyrimidine; fluoropyrimidine based ... See more keywords
P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-09859-x
Abstract: Nucleotide metabolism in cancer cells can influence malignant behavior and intrinsic resistance to therapy. Here we describe p53-dependent control of the rate-limiting enzyme in the pyrimidine catabolic pathway, dihydropyrimidine dehydrogenase (DPYD) and its effect on… read more here.
Keywords: dpyd; response; pyrimidine catabolic; p53 ... See more keywords
The Correlation Between DPYD*9A(c.85T>C) Genotype and Dihydropyrimidine Dehydrogenase Deficiency Phenotype in Patients With Gastrointestinal Malignancies Treated With Fluoropyrimidines
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Clinical Pathology"
DOI: 10.1093/ajcp/aqz112.056
Abstract: The correlation between DPYD*9A (c.85T>C) genotype and dihydropyrimidine dehydrogenase (DPD) deficiency phenotype is controversial. In a cohort of 28 patients, DPYD*9A was the most commonly diagnosed variant (46%) and there was a noticeable genotype-phenotype correlation.… read more here.
Keywords: phenotype; dpyd; correlation dpyd; genotype ... See more keywords
Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience
Sign Up to like & getrecommendations! Published in 2018 at "Dose-Response"
DOI: 10.1177/1559325818803042
Abstract: Background: Severe toxicity is experienced by a substantial minority of patients receiving fluoropyrimidine-based chemotherapy, with approximately 20% of these severe toxicities attributable to polymorphisms in the DPYD gene. The DPYD codes for the enzyme dihydropyrimidine… read more here.
Keywords: chemotherapy; dpyd; dihydropyrimidine dehydrogenase; colorectal cancer ... See more keywords
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis
Sign Up to like & getrecommendations! Published in 2017 at "BMC Cancer"
DOI: 10.1186/s12885-017-3406-2
Abstract: BackgroundTo evaluate a new UGT1A and DPYD polymorphism panel to better predict irinotecan-induced toxicity and the clinical response in Chinese patients with metastatic colorectal cancer (mCRC).MethodsThe genotypes of UGT1A (UGT1A1*6, UGT1A1*27, UGT1A1*28, UGT1A7*2, UGT1A7*3, UGT1A7*4… read more here.
Keywords: dpyd; ugt1a dpyd; irinotecan based; ugt1a1 ugt1a1 ... See more keywords
Prospective cohort study of the impact of hospital-wide dihydropyrimidine dehydrogenase (DPYD) genotype testing for fluoropyrimidine-based chemotherapy on adverse events and hospital costs.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.3028
Abstract: 3028 Background: Fluoropyrimidines remain integral components of modern chemotherapy for solid tumors, and their toxicities can be reduced by pretreatment DPYD genotyping. Our main objective was to demonstrate the feasibility of implementing a hospital-wide pretreatment… read more here.
Keywords: dpyd; hospital wide; pretreatment dpyd; fluoropyrimidine ... See more keywords
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1199462
Abstract: Background: Awareness about the importance of implementing DPYD pharmacogenetics in clinical practice to prevent severe side effects related to the use of fluoropyrimidines has been raised over the years. Since 2012 at the National Cancer… read more here.
Keywords: dpyd; national cancer; center; clinical practice ... See more keywords
Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29020045
Abstract: Simple Summary The combination of carboplatin and 5-fluorouracil (5-FU) is effective when used concurrently with radiotherapy for locoregionally advanced oropharyngeal carcinomas. DPYD polymorphisms can be associated with an increased risk of severe toxicity to fluoropyrimidines.… read more here.
Keywords: dpyd genotyping; dpyd; toxicity; upfront dpyd ... See more keywords